The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts

Table of Contents

Executive summary

• Vaccines and vaccine-preventable diseases
• Overview of the global vaccines market
• Pediatric vaccines
• Adult vaccines
• Pipeline analysis
• Competitive landscape

Chapter 1 Scope and methodology

• Scope
• Methodology

Chapter 2 Vaccines and vaccine-preventable

• diseases
• Summary
• Introduction
• Vaccines and the immune system
• The immune system
• Immunity by vaccination
• The history of vaccination
• Types of vaccines
• Hurdles in vaccine development
• Vaccine-preventable diseases
  • Measles
  • Mumps
  • Rubella
  • Diphtheria
  • Tetanus
  • Pertussis
  • Meningitis (pneumococcus, meningococcus and Hib)
  • Varicella
  • Hepatitis
  • Influenza
  • Typhoid
  • Rabies

Chapter 3 Overview of the global vaccines

• market
• Summary
• Introduction
• Key trends, issues and events
• Prophylactic cancer vaccines redefine the market
• US health reforms and VFC recommendations may influence vaccines sales
• Therapeutic vaccines: a franchise in the making
• Cell culture and adjuvant technology: next-generation vaccine engineering
• Seasonal influenza vaccines: key to continuous revenue generation
• Novel combination vaccines driving growth of vaccines for infectious
• diseases
• Leading vaccine brands
• Sales forecasts of leading vaccine brands
• Country market analysis
• Leading players in the vaccines market

Chapter 4 Pediatric vaccines

• Summary
• Introduction
• Pediatric immunization schedule
• Pediatric vaccine population
• Pneumococcal vaccines
• Leading brands
• Competitive analysis
• Diphtheria, tetanus and pertussis (DTP) vaccines
• Leading brands
• Competitive analysis
• Measles, mumps and rubella (MMR) vaccines
• Leading brands
• Competitive analysis
  • Market transition from MMR to MMRV
• Rotaviral vaccines
• Leading rotaviral vaccine brands
• Competitive analysis
• Meningococcal vaccines
• Leading meningococcal vaccine brands
• Competitive analysis
• Other pediatric vaccines
• Leading brands
• Competitive analysis

Chapter 5 Adult vaccines

• Summary
• Introduction
• Adult vaccine population
• Adolescent vaccination
• Elderly vaccination
• Traveler vaccination
• Hepatitis vaccines
• Leading brands
• Competitive analysis
• Influenza vaccines
• H1N1 swine flu
• Leading brands
• Competitive analysis
• Human papillomavirus (HPV) vaccines
• Leading brands
• Competitive analysis
• Other adult vaccines
• Leading brands

Chapter 6 Pipeline analysis

• Summary
• Introduction
• Vaccines under research and development
  • Prevnar 13vPnC
  • Menveo
  • MenB
  • Cervarix
  • Synflorix
  • Ixiaro/Jespect
• Newer vaccine strategies: DNA and therapeutic vaccines
  • DNA vaccines
  • Therapeutic vaccines
  • Provenge
• Pipeline forecasts

Chapter 7 Competitive landscape

• Summary
• Introduction
• Market concentration/fragmentation analysis
• Segment wise positioning of the five major players
• Forecast sales of leading players in the global vaccines market, 2008 - 14
• Merck
  • Overview
  • Marketed portfolio
  • Pipeline portfolio
  • Licensing agreements/mergers/acquisitions
  • Strategic and growth analysis
• GSK
  • Overview
  • Marketed portfolio
  • Pipeline portfolio
  • Licensing agreements/mergers/acquisitions
  • Strategic and growth analysis
• Wyeth
  • Overview
  • Marketed portfolio
  • Pipeline portfolio
  • Licensing agreements/mergers/acquisitions
  • Strategic and growth analysis
• Sanofi-Aventis
  • Overview
  • Marketed portfolio
  • Pipeline portfolio
  • Licensing agreements/mergers/acquisitions
  • Strategic and growth analysis
• Novartis
  • Overview
  • Marketed portfolio
  • Pipeline portfolio
  • Licensing agreements/mergers/acquisitions
  • Strategic and growth analysis

Chapter 8 Appendix

• Herfindahl Index
• Glossary

List of Figures

• Figure 2.1: Brief history of vaccines and the future
• Figure 4.2: Pediatric vaccination schedule for the US and 5EU, 2008
• Figure 6.3: Key recent and expected launches, 2009 - 14
• Figure 6.4: Ongoing clinical trials of therapeutic vaccines for cancer and HIV/AIDS, May 2009
• Figure 7.5: Competitive position of leading companies across market segments, 2008

List of Tables

• Table 2.1: Vaccine-preventable diseases
• Table 3.2: Global sales of leading vaccine brands, 2008
• Table 3.3: Sales forecast of leading vaccine brands, 2008 - 14
• Table 3.4: 7MM, 7EM and global sales of vaccine types (ATC classes), 2008
• Table 3.5: Sales of vaccines by country
• Table 3.6: Global sales of leading vaccine players, 2008
• Table 4.7: Births and catch-up population across the 7MM and 7EM, 2008
• Table 4.8: Leading pneumococcal vaccine brands, 2008
• Table 4.9: Leading DTP vaccine brands, 2008
• Table 4.10: Leading MMR vaccine brands, 2008
• Table 4.11: Leading rotaviral vaccine brands, 2008
• Table 4.12: Leading meningococcal vaccine brands, 2008
• Table 4.13: Prevalence pattern of Neisseria meningitidis serotypes
• Table 4.14: Other leading pediatric vaccines, 2008
• Table 5.15: Adolescent, adult and elderly population across the 7MM and 7EM, 2008
• Table 5.16: Traveler vaccines
• Table 5.17: Leading hepatitis vaccine brands, 2008
• Table 5.18: Leading influenza vaccine brands, 2008
• Table 5.19: Leading HPV vaccine brands, 2008
• Table 5.20: Other leading adult vaccine brands, 2008
• Table 6.21: An overview of Prevnar 13vPnC
• Table 6.22: An overview of Menveo
• Table 6.23: An overview of MenB
• Table 6.24: An overview of Cervarix
• Table 6.25: An overview of Synflorix
• Table 6.26: An overview of Ixiaro
• Table 6.27: Status quo of conceptualized therapeutic vaccines
• Table 6.28: An overview of Provenge
• Table 6.29: Sales forecast of leading recently marketed or late-stage pipeline vaccine candidates, 2008-14
• Table 7.30: Sales forecast of the leading players in the global vaccines market, 2008-14
• Table 7.31: Merck' s leading vaccine brands, 2008
• Table 7.32: Merck' s key vaccines under development, June 2009
• Table 7.33: Deals and alliances involving Merck, May 2009
• Table 7.34: GSK' s leading vaccine brands, 2008
• Table 7.35: GSK' s key vaccines under development, May 2009
• Table 7.36: Deals and alliances involving GSK, May 2009
• Table 7.37: Wyeth' s leading vaccine brands, 2008
• Table 7.38: Wyeth' s key vaccines under development, May 2009
• Table 7.39: Deals and alliances involving Wyeth, May 2009
• Table 7.40: Sanofi-Aventis' leading vaccine brands, 2008
• Table 7.41: Sanofi-Aventis' key vaccines under development, May 2009
• Table 7.42: Deals and alliances involving Sanofi-Aventis, May 2009
• Table 7.43: Novartis' leading vaccine brands, 2008
• Table 7.44: Novartis' key vaccines under development, May 2009
• Table 7.45: Deals and alliances involving Novartis, May 2009